
[EPISODE 25] Adam Stasio Talks, Large Data Sets, Breaking Down Problems, and Tech-Driven Solutions
On this episode of Molecular Moments, Jim McNally, Ph.D., speaks with Adam Stasio, president of SciMed, whose mission is to
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Jim McNally, Ph.D., speaks with Adam Stasio, president of SciMed, whose mission is to
This is the final blog in our three-part flow cytometry series. Part 1 highlighted the broad application of flow cytometry
In this article, Chief Scientific Officer at BioAgilytix, Jim McNally, Ph.D., explores why bioanalysts should prepare for the impending wave
Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
PCR platforms and Good Manufacturing Practices (GMP) certification further enhance European service offerings HAMBURG, GERMANY and DURHAM, NC, May 8,
BioAgilytix continues to build leadership in Europe. Hamburg, Germany April 3, 2023 – BioAgilytix, a leading global bioanalytical laboratory, today
This is the final blog in our three-part flow cytometry series. Part 1 highlighted the broad application of flow cytometry
As we continue our blog series on flow cytometry, we’ll now dive into how this powerful capability supports multiple types
Analytical testing of therapeutic compounds often requires data at the single-cell level. Flow cytometry is a versatile technology that can
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Jim McNally, Ph.D., speaks with Adam Stasio, president of SciMed, whose mission is to
This is the final blog in our three-part flow cytometry series. Part 1 highlighted the broad application of flow cytometry
In this article, Chief Scientific Officer at BioAgilytix, Jim McNally, Ph.D., explores why bioanalysts should prepare for the impending wave
Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
PCR platforms and Good Manufacturing Practices (GMP) certification further enhance European service offerings HAMBURG, GERMANY and DURHAM, NC, May 8,
BioAgilytix continues to build leadership in Europe. Hamburg, Germany April 3, 2023 – BioAgilytix, a leading global bioanalytical laboratory, today
This is the final blog in our three-part flow cytometry series. Part 1 highlighted the broad application of flow cytometry
As we continue our blog series on flow cytometry, we’ll now dive into how this powerful capability supports multiple types
Analytical testing of therapeutic compounds often requires data at the single-cell level. Flow cytometry is a versatile technology that can
For Highly Accurate Subpopulation Analysis
Flow cytometry is an accurate and effective method when used to identify and measure cellular biomarkers in complex subpopulations. BioAgilytix utilizes the Beckman Coulter CytoFLEX LX, BD FACSLyricâ„¢, and BD FACSCantoâ„¢ II flow cytometry platforms as part of our premier immunoassay facilities.
Flow cytometry platforms utilize a sophisticated array of lasers, optics, fluidics and electronic detectors to measure light scatter and/or fluorescence emission from cells, running them one at a time through a laser to quantitate physical properties of the cells, including cell size, granularity, and the amounts of target proteins. As cells pass through a laser, they absorb its light and then emit a specific color signal based on targeted fluorochromes, to determine the amount of each type of cell in the sample, or the amount of target expressed by the individual cells.
Flow cytometry allows for accurate and precise analyses of cell surface and intracellular molecules to better characterize and define cell types in a mixed or purified sample. It enables the high throughput, automated quantification of properties which include each particle’s relative size, granularity, internal complexity, and fluorescence intensity.
Our passion for the science of small and large molecule bioanalysis drives our ability to deliver premium, tailored services for biomarker, immunogenicity, pharmacokinetics (PK), and cell-based assays.
BioAgilytix typically uses its premier flow cytometry platforms for services involving immunogenicity, cell-based assays, and intricate immunophenotyping, oncological, and disease-associated biomarker analysis and monitoring. We also leverage this platform for DNA and RNA analysis, receptor & target occupancy assays, intracellular and surface marker analysis and/or phenotyping, whole cell and receptor binding assays, and in vitro toxicology, antibody screening, and rare event analysis, such as in dendritic cells and stem/progenitor cells.